Masayuki Futagami1, Yoshihito Yokoyama2, Kaori Iino1, Masahiko Aoki3, Tadahiro Shoji4, Toru Sugiyama4, Hisanori Ariga5, Hideki Tokunaga6, Tadao Takano6, Yoh Watanabe6, Nobuo Yaegashi6, Keiichi Jingu7, Naoki Sato8, Yukihiro Terada8, Akira Anbai9, Tsuyoshi Ohta10, Hirohisa Kurachi10, Yuuki Kuroda11, Hiroshi Nishiyama12, Keiya Fujimori12, Takafumi Watanabe12, Hisashi Sato13, Toru Tase14, Hitoshi Wada15, Hideki Mizunuma1. 1. Department of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine, 5-Zaifu-cho, Hirosaki, Aomori, 036-8562, Japan. 2. Department of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine, 5-Zaifu-cho, Hirosaki, Aomori, 036-8562, Japan. yokoyama@cc.hirosaki-u.ac.jp. 3. Department of Radiology and Radiation Oncology, Hirosaki University Graduate School of Medicine, 5-Zaifu-cho, Hirosaki, Aomori, 036-8562, Japan. 4. Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka, Japan. 5. Department of Radiation Oncology, Iwate Medical University School of Medicine, Morioka, Japan. 6. Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai, Japan. 7. Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan. 8. Department of Obstetrics and Gynecology, Akita University Graduate School of Medicine, Akita, Japan. 9. Department of Radiology and Radiation Oncology, Akita University Graduate School of Medicine, Akita, Japan. 10. Department of Obstetrics and Gynecology, Yamagata University Faculty of Medicine, Yamagata, Japan. 11. Department of Radiation Oncology, Yamagata University Faculty of Medicine, Yamagata, Japan. 12. Department of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, Fukushima, Japan. 13. Department of Radiation Oncology, Fukushima Medical University School of Medicine, Fukushima, Japan. 14. Department of Gynecology, Miyagi Cancer Center, Natori, Japan. 15. Department of Radiation Oncology, Miyagi Cancer Center, Natori, Japan.
Abstract
BACKGROUND: This multi-institutional study was conducted to clarify the clinicopathological features of squamous cell carcinomas of the vulva. METHODS: The medical records of vulvar cancer patients treated between 2002 and 2012 were retrospectively reviewed following approval by the Institutional Review Board of each institution. RESULTS: One hundred and eleven patients with vulvar malignancies were included. Of these, 63 patients had squamous cell carcinoma (57 %). Initial treatment was surgery, radiation therapy (RT), and concurrent chemoradiotherapy (CCRT) in 34 (54 %), 15 (24 %), and 11 (17 %) patients, respectively. Nineteen, 11, 26, and 7 patients had stage I, II, III, and IV disease, respectively. Of the 34 patients who had surgical treatment, 50 % had stage I disease, while 74 % of those who received CCRT had stage III or IV disease. Complete response (CR) rates for the surgery, RT, and CCRT groups were 73, 60, and 64 %, respectively. The 5-year survival rates for stage I/II and III/IV disease were 64 and 39 %, respectively (P = 0.019). The 5-year survival rates for the surgery, RT, and CCRT groups were 53, 38, and 50 %, respectively, and the prognosis of patients treated with surgery or CCRT was significantly better than that of patients who received RT (P < 0.05). In multivariate analysis, clinical response to initial treatment was an independent prognostic factor (P < 0.001). CONCLUSIONS: Although many patients had advanced-stage disease in the CCRT group, the therapeutic outcome for the surgery and CCRT groups was similar. Thus, CCRT may be a promising treatment for squamous cell carcinoma of the vulva.
BACKGROUND: This multi-institutional study was conducted to clarify the clinicopathological features of squamous cell carcinomas of the vulva. METHODS: The medical records of vulvar cancerpatients treated between 2002 and 2012 were retrospectively reviewed following approval by the Institutional Review Board of each institution. RESULTS: One hundred and eleven patients with vulvar malignancies were included. Of these, 63 patients had squamous cell carcinoma (57 %). Initial treatment was surgery, radiation therapy (RT), and concurrent chemoradiotherapy (CCRT) in 34 (54 %), 15 (24 %), and 11 (17 %) patients, respectively. Nineteen, 11, 26, and 7 patients had stage I, II, III, and IV disease, respectively. Of the 34 patients who had surgical treatment, 50 % had stage I disease, while 74 % of those who received CCRT had stage III or IV disease. Complete response (CR) rates for the surgery, RT, and CCRT groups were 73, 60, and 64 %, respectively. The 5-year survival rates for stage I/II and III/IV disease were 64 and 39 %, respectively (P = 0.019). The 5-year survival rates for the surgery, RT, and CCRT groups were 53, 38, and 50 %, respectively, and the prognosis of patients treated with surgery or CCRT was significantly better than that of patients who received RT (P < 0.05). In multivariate analysis, clinical response to initial treatment was an independent prognostic factor (P < 0.001). CONCLUSIONS: Although many patients had advanced-stage disease in the CCRT group, the therapeutic outcome for the surgery and CCRT groups was similar. Thus, CCRT may be a promising treatment for squamous cell carcinoma of the vulva.
Entities:
Keywords:
CCRT; Prognosis; Squamous cell carcinoma of the vulva; Surgery
Authors: David H Moore; Shamshad Ali; Wui-Jin Koh; Helen Michael; Mack N Barnes; Carolyn K McCourt; Howard D Homesley; Joan L Walker Journal: Gynecol Oncol Date: 2011-11-09 Impact factor: 5.482
Authors: U Beller; M A Quinn; J L Benedet; W T Creasman; H Y S Ngan; P Maisonneuve; S Pecorelli; F Odicino; A P M Heintz Journal: Int J Gynaecol Obstet Date: 2006-11 Impact factor: 3.561
Authors: Zaid M Tabbaa; Jesus Gonzalez; Jacek J Sznurkowski; Amy L Weaver; Andrea Mariani; William A Cliby Journal: Gynecol Oncol Date: 2012-06-13 Impact factor: 5.482
Authors: Sushil Beriwal; Gaurav Shukla; Ashwin Shinde; Dwight E Heron; Joseph L Kelley; Robert P Edwards; Paniti Sukumvanich; Scott Richards; Alexander B Olawaiye; Thomas C Krivak Journal: Int J Radiat Oncol Biol Phys Date: 2012-12-27 Impact factor: 7.038
Authors: C W Whitney; W Sause; B N Bundy; J H Malfetano; E V Hannigan; W C Fowler; D L Clarke-Pearson; S Y Liao Journal: J Clin Oncol Date: 1999-05 Impact factor: 44.544
Authors: Raymond H Mak; Lia M Halasz; Cynthia K Tanaka; Marek Ancukiewicz; Delray J Schultz; Anthony H Russell; Akila N Viswanathan Journal: Gynecol Oncol Date: 2010-10-14 Impact factor: 5.482